MDS: Clinical Trials

23 trials for MDS, newest first

ClinicalTrials Daily  ·  Areas  ·  Conditions  ·  Drugs  ·  Sponsors  ·  

23 completed. 23 Phase 1, 5 Phase 2.

By phase and status

PhaseTrialsStatus
Phase 123Completed 23
Phase 25Completed 5

Follow MDS: new trials by email Literature Review of MDS trials Research Report on MDS

Trials (filtered) newest first · largest first

All 23 trials

Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.

TrialPhaseStatusSponsorEnrollmentStartUpdated
A Phase 1 Study With LYT-200 in Patients With Relapsed/Refractory Acute Myeloid Leukemia (AML), or With Relapsed/Refractory, High-risk Myelodysplastic Syndrome (MDS)
LYT-200, Venetoclax, Azacitidine - AML, Adult Recurrent, MDS
Phase 1CompletedPureTech1012022-12-122026-05-06
Safety and Efficacy of Allogeneic NK Cell Infusions in Patients With Relapsed/Refractory AML and High Risk MDS
DVX201 - AML, Adult Recurrent, MDS
Phase 1CompletedCoeptis Therapeutics82021-12-152024-07-19
A Safety and Efficacy Study of SHR-1702 Monotherapy in Patients With Acute Myeloid Leukemia (AML) or Myelodysplastic Syndrome (MDS)
SHR-1702 - AML, MDS
Phase 1CompletedJiangsu HengRui Medicine Co., Ltd.312020-09-102023-08-24
Haplo Peripheral Blood Sct In GVHD Prevention
FLUDARABINE, CYCLOPHOSPHAMIDE, TBI - GVHD, AML
Phase 1CompletedZachariah Michael DeFilipp252020-08-142025-07-20
CYC065 CDK Inhibitor and Venetoclax Study in Relapsed/Refractory AML or MDS
CYC065, Venetoclax - AML, MDS
Phase 1CompletedCyclacel Pharmaceuticals, Inc.142019-08-022024-09-19
DEPLETHINK - LymphoDEPLEtion and THerapeutic Immunotherapy With NKR-2
NKR-2 - AML, MDS
Phase 1 / Phase 2CompletedCelyad Oncology SA212018-09-182021-05-04
Pevonedistat and Low Dose Cytarabine in Adult Patients With AML and MDS
Pevonedistat, Cytarabine - Acute Myelogenous Leukemia, AML
Phase 1CompletedJustin Watts, MD122018-05-212021-12-28
CX-01 Combined With Azacitidine in the Treatment of Relapsed or Refractory Myelodysplastic Syndrome and Acute Myeloid Leukemia
CX-01, Azacitidine, Bone marrow biopsy - Myelodysplastic Syndromes, Acute Myeloid Leukemia
Phase 1CompletedWashington University School of Medicine202017-04-072019-12-05
Nonmyeloablative Hematopoietic Cell Transplantation (HCT) for Patients With Hematologic Malignancies Using Related, HLA-Haploidentical Donors: A Pilot Trial of Peripheral Blood Stem Cells (PBSC) as the Donor Source
Fludarabine, Cyclophosphamide, Mesna - Leukemia, MDS
Phase 1CompletedRafic Farah, MD282015-02-112019-10-15
A Study of LDE255 in Combination With Azacitidine for High Risk Myelodysplastic Syndrome Patients
Azacitidine and LDE255 - MDS
Phase 1CompletedGroupe Francophone des Myelodysplasies232015-02-102018-12-06
Pharmacokinetic Guided Dose Escalation and Dose Confirmation With Oral Decitabine and Oral Cytidine Deaminase Inhibitor (CDAi) in Patients With Myelodysplastic Syndromes (MDS)
ASTX727 Dose Escalation, ASTX727 Dose Confirmation, ASTX727 Fixed-Dose Combination - Myelodysplastic Syndrome, MDS
Phase 1 / Phase 2CompletedAstex Pharmaceuticals, Inc.1302014-10-282024-08-27
Ultra-Low Dose IL-2 Therapy as GVHD Prophylaxis in Haploidentical Allogeneic Stem Cell Transplantation
CliniMACS CD34 selection system, ULD IL-2 - Acute Lymphoblastic Leukemia (ALL), Acute Myelogenous Leukemia (AML)
Phase 1CompletedNational Heart, Lung, and Blood Institute (NHLBI)242014-08-262018-07-05
Study of FF-10501-01 in Patients With Relapsed or Refractory Hematological Malignancies
FF-10501-01 - AML, CMML
Phase 1 / Phase 2CompletedFujifilm Pharmaceuticals U.S.A., Inc.552014-07-012025-03-19
Decitabine Combining Modified CAG Followed by HLA Haploidentical Peripheral Blood Mononuclear Cells Infusion for Elderly Patients With Acute Myeloid Leukemia(AML)
Decitabine, Cytarabine, aclacinomycin - MDS, AML
Phase 1 / Phase 2CompletedChinese PLA General Hospital292012-11-012016-02-25
SGI-110 in Participants With Myelodysplastic Syndromes (MDS) or Acute Myelogenous Leukemia (AML)
Guadecitabine - MDS, CMML
Phase 1 / Phase 2CompletedAstex Pharmaceuticals, Inc.4142011-01-042025-01-23
Phase 1 Study of TG02 Citrate in Patients With Advanced Hematological Malignancies
TG02 citrate, Carfilzomib, Dexamethasone - AML, ALL
Phase 1CompletedTragara Pharmaceuticals, Inc.1202010-08-012016-05-06
STA-9090 for Treatment of AML, CML, MDS and Myeloproliferative Disorders
STA-9090 (ganetespib) - AML, CML
Phase 1CompletedSynta Pharmaceuticals Corp.312009-03-012014-09-18
Umbilical Cord Blood Transplant for Hematological Malignancies
Ex Vivo CD3/CD28 costimulated Umbilical Cord Blood T cells, Observation Arm - CML, AML
Phase 1CompletedUniversity of Pennsylvania52009-01-012016-08-19
Pharmacokinetics and Safety Study of Azacitidine in Cancer Patients With and Without Impaired Renal Function
azacitidine - MDS, AML
Phase 1CompletedCelgene312008-11-012019-11-19
Safety Study of IL-7 in Recipients of a Hemopoietic Stem Cell Transplant Peripheral Blood Stem Cell Transplant
CYT107 - Recombinant glycosylated human interleukin 7., rhIL-7 (CYT107) - AML, CML
Phase 1CompletedCytheris, Inc.122008-03-012012-07-26

Showing 20 of 23. Sign in to see all of them.

Narrower conditions

Leukemia, Myeloid, Acute (9)  ·  Myelodysplastic Syndromes (7)  ·  Recurrence (4)  ·  Hodgkin Disease (3)  ·  Leukemia (3)  ·  Multiple Myeloma (3)  ·  Graft vs Host Disease (2)  ·  Hematologic Neoplasms (2)  ·  Leukemia, Myelomonocytic, Chronic (2)  ·  Lymphoma, Non-Hodgkin (2)  ·  Myeloproliferative Disorders (2)  ·  Precursor Cell Lymphoblastic Leukemia-Lymphoma (2)  ·  Primary Myelofibrosis (2)  ·  Anemia, Aplastic (1)  ·  Aortic aneurysm, familial thoracic 4 (1)

Broader conditions

Hematologic Diseases (18)  ·  Hemic and Lymphatic Diseases (18)  ·  Neoplasms (16)  ·  Neoplasms by Histologic Type (14)  ·  Bone Marrow Diseases (12)  ·  Leukemia, Myeloid (10)  ·  Leukemia (9)  ·  Disease Attributes (8)  ·  Immune System Diseases (8)  ·  Pathologic Processes (8)  ·  Pathological Conditions, Signs and Symptoms (8)  ·  Immunoproliferative Disorders (6)  ·  Lymphoproliferative Disorders (6)  ·  Lymphatic Diseases (5)  ·  Chronic Disease (4)

Interventions

Azacitidine (4)  ·  Cyclophosphamide (3)  ·  Decitabine (3)  ·  fludarabine (3)  ·  Cytarabine (2)  ·  Granulocyte Colony-Stimulating Factor (2)  ·  Mycophenolic Acid (2)  ·  fludarabine phosphate (2)  ·  venetoclax (2)  ·  CYC065 (1)  ·  Calcium Dobesilate (1)  ·  Dexamethasone (1)  ·  Filgrastim (1)  ·  Interleukin-7 (1)  ·  Melphalan (1)

Sponsors

Astex Pharmaceuticals, Inc. (2)  ·  Celgene (1)  ·  Celyad Oncology SA (1)  ·  Chinese PLA General Hospital (1)  ·  Coeptis Therapeutics (1)  ·  Cyclacel Pharmaceuticals, Inc. (1)  ·  Cytheris, Inc. (1)  ·  Daiichi Sankyo (1)  ·  Fujifilm Pharmaceuticals U.S.A., Inc. (1)  ·  Groupe Francophone des Myelodysplasies (1)  ·  Jiangsu HengRui Medicine Co., Ltd. (1)  ·  Joanne Kurtzberg, MD (1)  ·  Justin Watts, MD (1)  ·  M.D. Anderson Cancer Center (1)  ·  National Heart, Lung, and Blood Institute (NHLBI) (1)

Countries

United States (20)  ·  Canada (2)  ·  China (2)  ·  Belgium (1)  ·  France (1)  ·  Georgia (1)

Top investigators

Aleksandra Filipovic, MD, PhD. (1)  ·  David A Rizzieri, MD (1)  ·  David Porter, MD (1)  ·  Elizabeth Hexner, MD (1)  ·  Frederic Lehmann, MD (1)  ·  Gautam Borthakur, MD (1)  ·  Guillermo Garcia-Manero, MD (1)  ·  James Lowder, MD (1)  ·  Jay Backstrom, MD (1)  ·  Joanne Kurtzberg, MD (1)  ·  Jorge E. Cortes, MD (1)  ·  Justin Watts, MD (1)  ·  Li Yu, M.D. Ph.D. (1)  ·  Marcel van den Brink, MD, PhD (1)

Results publications

PMID 23012326, PMID 24002496, PMID 26296954, PMID 26858124, PMID 28881839, PMID 30926081, PMID 31060979, PMID 31331399, PMID 32264726, PMID 32285126, PMID 32645016